On Thursday, Novavax Inc (NVAX) stock saw a decline, ending the day at $9.92 which represents a decrease of $-0.08 or -0.80% from the prior close of $10. The stock opened at $10 and touched a low of ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s ...

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years ...

Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.

A single adverse event halts trials for Novavax's COVID-19 and influenza combination vaccine, raising concerns but leaving its standalone COVID-19 vaccine unaffected ...

As of 21 October at 3:10 pm GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.